U.S. gives full approval to Lecanemab to treat Alzheimer’s disease and will fund its use

Miguel Jiménez – Article published in El País, 07/06, 2023

Leqembi (Lecanemab) becomes the first ever disease-modifying therapy to treat Alzheimer’s disease to gain full FDA approval. Currently, more than 6 million Americans live with this neurodegenerative disease.

The FDA approval includes a box label warning about the drug’s known side effects, which include brain swelling and tiny bleeds.

The FDA approval is expected to trigger Medicare coverage for the $26,500-a-year drug.

Full article (spanish)